Tsuchimochi, Wakaba <br/><br/>
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.  [electronic resource] 

 -  Endocrine journal  2015 
 - 13-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1348-4540 
<br/><br/><label>Standard No.: </label>10.1507/endocrj.EJ14-0393  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Blood Glucose--analysis<br/>Combined Modality Therapy--adverse effects<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Gastric Inhibitory Polypeptide--agonists<br/>Glucagon--antagonists & inhibitors<br/>Glucagon-Like Peptide 1--agonists<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--prevention & control<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin--administration & dosage<br/>Insulin Resistance<br/>Japan<br/>Middle Aged<br/>Monitoring, Ambulatory<br/>Postprandial Period<br/>Pyrazoles--adverse effects<br/>Thiazolidines--adverse effects